Conmed Corp (CNMD) Q2 2024 Earnings Call Highlights: Record Sales Amid Supply Chain Challenges

GuruFocus News
4 min read

In This Article:

  • Total Sales: $332 million, a year-over-year increase of 4.5% as reported and 5.2% in constant currency.

  • GAAP Net Income: $30 million, compared to $13.7 million in Q2 2023.

  • Adjusted Net Income: $30.6 million, an increase of 17.2% year-over-year.

  • Adjusted Diluted EPS: $0.98, an increase of 18.1% year-over-year.

  • Gross Margin: 55.3%, an increase of 90 basis points compared to the prior year quarter.

  • Cash Flow from Operations: $43.3 million, compared to $26.7 million in Q2 2023.

  • Capital Expenditures: $3.6 million, compared to $4.5 million a year ago.

  • Long-term Debt: $965.2 million, down from $990.1 million as of March 31.

  • Leverage Ratio: 3.8 times as of June 30.

  • U.S. Sales Growth: 6.1% year-over-year.

  • International Sales Growth: 4.0% year-over-year.

  • Worldwide Orthopedics Sales: Declined 0.1% in Q2.

  • Worldwide General Surgery Revenue: Increased 9.4% in Q2.

  • Adjusted SG&A Expenses: 36.9% of sales, 50 basis points lower than the prior year quarter.

  • Adjusted Interest Expense: $8.2 million in Q2.

  • Adjusted Effective Tax Rate: 24.0% in Q2.

Release Date: July 31, 2024

For the complete transcript of the earnings call, please refer to the full earnings call transcript.

Positive Points

  • Conmed Corp (NYSE:CNMD) achieved a record high quarterly sales result with total sales of $332 million, marking a year-over-year increase of 4.5% as reported and 5.2% in constant currency.

  • The company's GAAP net income for the second quarter was $30 million, more than doubling from $13.7 million in the same quarter of 2023.

  • Adjusted net income increased by 17.2% year-over-year, and adjusted diluted net earnings per share rose by 18.1%, indicating strong financial performance.

  • General surgery revenue showed robust growth, increasing by 9.4% worldwide, with U.S. revenue up by 8.9% and international revenue by 10.5%.

  • Conmed Corp (NYSE:CNMD) improved its leverage ratio to 3.8 times, better than expected, and demonstrated strong cash flow from operations, which increased to $43.3 million from $26.7 million in the previous year.

Negative Points

  • The orthopedic segment faced supply chain challenges, leading to a decline of 0.1% in worldwide sales, with U.S. sales down by 0.4%.

  • Supply constraints in key implantables, particularly in sports medicine and foot and ankle businesses, have not been resolved as quickly as anticipated.

  • The company had to lower its guidance for the remainder of the year due to ongoing supply chain issues, impacting its ability to fully capitalize on market opportunities.

  • Conmed Corp (NYSE:CNMD) experienced unexpected supplier closures, which disrupted production and contributed to inefficiencies.

  • The company acknowledged that its margin expansion targets for 2024 and 2025 might be delayed due to current supply chain challenges.

Recommended Stories